RAI Files Citizens Petition Requesting Vital’s ELAD Development Be Put on Hold

January 25, 2016—Rosalind Advisors, Inc. (“RAI”) filed a citizen petition requesting that the Food and Drug Administration place the extracorporeal liver assist device (“ELAD”) being developed by Vital Therapies, Inc. on Clinical Hold. RAI cites the ELAD’s treatment emergent adverse effect (“TEAE”) profile, and states that Vital’s “proposed phase 3 trial VTI-308 is not adequate and well-controlled.”

By: Katherine E. Adams

View Attachment (PDF)